68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours

Abstract

In conclusion, (68)Ga DOTA-NOC PET was more accurate than CT for the identification of bone lesions and led to a change in clinical management in nine patients with a negative CT scan.

Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

“…68 Ga-DOTATATE PET/CT showed high sensitivity (.94%) and specificity (.92%) for NEN lesion localization, with the highest accuracy being for primary midgut tumors. The results of that study are in line with those of much smaller previous studies using PET/CT with either 68 Ga-DOTATOC or 68 Ga-DOTANOC (16,20,(43)(44)(45)(46). Overall, SSR PET/CT showed a high accuracy ($96%) for the detection of welldifferentiated NENs at either the primary site or the metastatic sites (mostly lymph nodes, liver, bone, and lung) (20,39,44).…”

Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT

“…68 Ga-DOTANOC PET/CT has been used for staging, restaging, controlling therapy, and detecting unknown primary tumors in patients with NET (9)(10)(11). Compared with other radiopharmaceuticals, such as 18 F-FDG and 18 F-3,4-dihydroxyphenylalanine (12)(13)(14), or other conventional imaging methods, such as CT or bone scanning (15,16), 68 Ga-DOTANOC has proved to be more accurate in the diagnosis of NET.…”

Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs)

“…SPECT-CT studies with 99m Tc-EDDA/HYNIC-TOC resulted in exact pre-surgical and pre-treatment N/M staging of bronchial and thymic NETs, except in one case where total massive bilateral suprarenal metastatic lesions were detected only on the CT part of SPECT-CT images without tracer uptake and in two cases with negative multiple hepatic lesions. These results were described as false negative, probably due to necrotic process and metastatic cell dedifferentiation with Original absence of somatostatin-receptor expression [10][11][12][13][14][15][16][17][18][19][20][21][22]. Positive imaging results concerning benign thyroid adenoma and suprarenal adenoma could be explained with moderate somatostatin-receptor expression, described in some benign tumors and inflammation [10,22,23].…”

“…A high incidence and density of somatostatin receptors (SSTR2, SSTR3, and SSTR5) are found in thoracic NETs [9,10]. Several somatostatin analogs with high affinity to these receptors have been developed for diagnosis and Original therapy [11][12][13][14][15][16][17]. According to the ENETS recommendations 2015, the functional hybrid PET-CT and SPECT-CT imaging modalities with radiolabeled somatostatin analogs has important role in diagnosis, staging and follow up of patients with bronchial and mediastinal NETs, since these methods are more specific than conventional imaging techniques especially for typical and atypical carcinoids [2]; somatostatin-receptor SPECT-CT/PET-CT studies can also predict the response to peptide receptor radionuclide therapy (PRRT) [1,2].…”